HRP20230283T1 - Nutriceutički oftalmološki pripravak za liječenje patoloških stanja retine koja imaju neovaskularnu komponentu - Google Patents
Nutriceutički oftalmološki pripravak za liječenje patoloških stanja retine koja imaju neovaskularnu komponentu Download PDFInfo
- Publication number
- HRP20230283T1 HRP20230283T1 HRP20230283TT HRP20230283T HRP20230283T1 HR P20230283 T1 HRP20230283 T1 HR P20230283T1 HR P20230283T T HRP20230283T T HR P20230283TT HR P20230283 T HRP20230283 T HR P20230283T HR P20230283 T1 HRP20230283 T1 HR P20230283T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- use according
- group
- vegf
- days
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 3
- 239000002417 nutraceutical Substances 0.000 title claims 2
- 235000021436 nutraceutical agent Nutrition 0.000 title claims 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000001525 retina Anatomy 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims 5
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 2
- 229930003268 Vitamin C Natural products 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims 2
- 229910052802 copper Inorganic materials 0.000 claims 2
- 239000010949 copper Substances 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 2
- 235000021323 fish oil Nutrition 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 235000012680 lutein Nutrition 0.000 claims 2
- 229960005375 lutein Drugs 0.000 claims 2
- 239000001656 lutein Substances 0.000 claims 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 2
- 239000006014 omega-3 oil Substances 0.000 claims 2
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 2
- 235000021283 resveratrol Nutrition 0.000 claims 2
- 229940016667 resveratrol Drugs 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 235000019154 vitamin C Nutrition 0.000 claims 2
- 239000011718 vitamin C Substances 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 2
- 235000010930 zeaxanthin Nutrition 0.000 claims 2
- 239000001775 zeaxanthin Substances 0.000 claims 2
- 229940043269 zeaxanthin Drugs 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 108010043116 abicipar pegol Proteins 0.000 claims 1
- 229950008281 abicipar pegol Drugs 0.000 claims 1
- 108010081667 aflibercept Proteins 0.000 claims 1
- 229960002833 aflibercept Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229950000025 brolucizumab Drugs 0.000 claims 1
- 235000021466 carotenoid Nutrition 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 1
- 229940116862 faricimab Drugs 0.000 claims 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Oftalmološki nutriceutički pripravak koji sadrži resveratrol, poželjno u količini većoj od 20 mg, za uporabu u liječenju očne bolesti kod subjekta koji prima anti-VEGF tretman.
2. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time što pripravak sadrži količinu veću od ili jednaku 30 mg resveratrola, poželjno veću od 30 mg, još poželjnije veću od ili jednaku 50 mg.
3. Pripravak za uporabu prema jednom od prethodnih patentnih zahtjeva, naznačen time što pripravak dodatno sadrži:
- vitamine, poželjno odabrane iz grupe koja se sastoji od vitamina C i vitamina E;
- mikroelemente, poželjno odabrane iz grupe koja se sastoji od cinka i bakra;
- karotenoide, poželjno odabrane iz grupe koja se sastoji od zeaksantina i luteina;
- omega-3 masne kiseline, poželjno iz ribljeg ulja, još poželjnije odabrane iz grupe koja se sastoji od eikozapentanske kiseline (EPA) i dokozaheksanske kiseline (DHA).
4. Pripravak za uporabu prema jednom od prethodnih patentnih zahtjeva, naznačen time što pripravak sadrži:
- vitamin C, poželjno od 50 mg do 500 mg, još poželjnije 120 mg;
- vitamin E, poželjno od 10 mg do 500 mg, još poželjnije 30 mg
- cink, poželjno od 5 mg do 100 mg, još poželjnije 12.5 mg;
- bakar, poželjno od 0.2 mg do 10 mg, još poželjnije 1 mg;
- lutein, poželjno od 2 mg do 50 mg, još poželjnije 20 mg;
- zeaksantin, poželjno od 0.5 mg do 10 mg, još poželjnije 4 mg;
- omega-3 masne kiseline iz ribljeg ulja, poželjno od 100 mg do 1000 mg, još poželjnije od 800 mg do 1000 mg.
5. Pripravak za uporabu prema jednom od prethodnih patentnih zahtjeva, naznačen time što se pripravak primjenjuje oralno.
6. Pripravak za uporabu prema jednom od prethodnih patentnih zahtjeva, naznačen time što se pripravak primjenjuje na dnevnoj bazi.
7. Pripravak za uporabu prema jednom od prethodnih patentnih zahtjeva, naznačen time što anti-VEGF tretman odgovara primjeni inhibitora VEGF signalnog puta, poželjno odabranog iz sljedeće skupine: antitijelo, fragment antitijela, rekombinantni protein, fuzioni protein i njihove smjese.
8. Pripravak za uporabu prema jednom od prethodnih patentnih zahtjeva, naznačen time što je inhibitor odabran iz sljedeće skupine: ranibizumab, bevacizumab, aflibercept, abicipar pegol, konbercept, faricimab, brolucizumab i njihove smjese.
9. Pripravak za uporabu prema jednom od prethodnih patentnih zahtjeva, naznačen time što se anti-VEGF tretman primjenjuje intravitrealnom injekcijom ili topikalno.
10. Pripravak za uporabu prema jednom od prethodnih patentnih zahtjeva, naznačen time što je očna bolest odabrana iz skupine koja se sastoji od senilne makularne degeneracije, dijabetičkog makularnog edema, okluzije retinalne vene, miopijske koroidalne neovaskularizacije, neovaskularnog glaukoma i proliferativne dijabetičke retinopatije.
11. Pripravak kao što je definiran u bilo kojem od patentnih zahtjeva 1 do 4 za istovremenu, odvojenu ili sekvencijalnu uporabu sa anti-VEGF agensom, poželjno kao što je definiran u patentnim zahtjevima 7 i 8, u liječenju očne bolesti, poželjno odabrane iz skupine koja se sastoji od senilne makularne degeneracije, dijabetičkog makularnog edema, okluzije retinalne vene, miopijske koroidalne neovaskularizacije, neovaskularnog glaukoma i proliferativne dijabetičke retinopatije.
12. Pripravak za uporabu prema patentnom zahtjevu 11, naznačen time što se pripravak primjenjuje oralno, poželjno na dnevnoj bazi.
13. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 11 ili 12, naznačen time što se anti-VEGF agens primjenjuje intravitrealnom injekcijom ili topikalno.
14. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 11 do 13, naznačen time što su doza i/ili frekvencija primjene anti-VEGF agensa smanjene u usporedbi s dozom i/ili frekvencijom koje se primjenjuju kod subjekta koji ne prima pripravak.
15. Pripravak za uporabu prema patentnom zahtjevu 14, naznačen time što je interval između dvije primjene anti-VEGF agensa duži od 30 dana, poželjno duži od 45 dana, poželjno duži od 60 dana ili čak duži od 75 dana, poželjnije duži od 90 dana, u usporedbi s intervalom između dvije primjene anti-VEGF agensa kod subjekta koji ne prima pripravak.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306772 | 2018-12-20 | ||
| PCT/EP2019/086174 WO2020127641A1 (fr) | 2018-12-20 | 2019-12-19 | Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire |
| EP19829158.5A EP3897595B1 (fr) | 2018-12-20 | 2019-12-19 | Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230283T1 true HRP20230283T1 (hr) | 2023-05-12 |
Family
ID=65200511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230283TT HRP20230283T1 (hr) | 2018-12-20 | 2019-12-19 | Nutriceutički oftalmološki pripravak za liječenje patoloških stanja retine koja imaju neovaskularnu komponentu |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3897595B1 (hr) |
| CA (1) | CA3122227A1 (hr) |
| DK (1) | DK3897595T3 (hr) |
| ES (1) | ES2940767T3 (hr) |
| FI (1) | FI3897595T3 (hr) |
| HR (1) | HRP20230283T1 (hr) |
| HU (1) | HUE061286T2 (hr) |
| LT (1) | LT3897595T (hr) |
| MA (1) | MA54511B1 (hr) |
| PL (1) | PL3897595T3 (hr) |
| PT (1) | PT3897595T (hr) |
| RS (1) | RS64066B1 (hr) |
| SI (1) | SI3897595T1 (hr) |
| UA (1) | UA127874C2 (hr) |
| WO (1) | WO2020127641A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3099551A1 (en) | 2018-05-10 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3034018B1 (fr) | 2015-03-25 | 2017-11-03 | Thea Lab | Composition ophtalmique nutraceutique pour la sante oculaire |
-
2019
- 2019-12-19 WO PCT/EP2019/086174 patent/WO2020127641A1/fr unknown
- 2019-12-19 CA CA3122227A patent/CA3122227A1/fr active Pending
- 2019-12-19 PL PL19829158.5T patent/PL3897595T3/pl unknown
- 2019-12-19 ES ES19829158T patent/ES2940767T3/es active Active
- 2019-12-19 HR HRP20230283TT patent/HRP20230283T1/hr unknown
- 2019-12-19 UA UAA202103400A patent/UA127874C2/uk unknown
- 2019-12-19 HU HUE19829158A patent/HUE061286T2/hu unknown
- 2019-12-19 SI SI201930498T patent/SI3897595T1/sl unknown
- 2019-12-19 RS RS20230215A patent/RS64066B1/sr unknown
- 2019-12-19 DK DK19829158.5T patent/DK3897595T3/da active
- 2019-12-19 EP EP19829158.5A patent/EP3897595B1/fr active Active
- 2019-12-19 LT LTEPPCT/EP2019/086174T patent/LT3897595T/lt unknown
- 2019-12-19 FI FIEP19829158.5T patent/FI3897595T3/en active
- 2019-12-19 PT PT198291585T patent/PT3897595T/pt unknown
- 2019-12-19 MA MA54511A patent/MA54511B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI3897595T3 (en) | 2023-03-31 |
| DK3897595T3 (da) | 2023-03-27 |
| WO2020127641A1 (fr) | 2020-06-25 |
| EP3897595B1 (fr) | 2023-03-15 |
| RS64066B1 (sr) | 2023-04-28 |
| SI3897595T1 (sl) | 2023-04-28 |
| CA3122227A1 (fr) | 2020-06-25 |
| MA54511A (fr) | 2022-03-30 |
| PL3897595T3 (pl) | 2023-05-08 |
| ES2940767T3 (es) | 2023-05-11 |
| EP3897595A1 (fr) | 2021-10-27 |
| LT3897595T (lt) | 2023-04-25 |
| UA127874C2 (uk) | 2024-01-31 |
| HUE061286T2 (hu) | 2023-06-28 |
| MA54511B1 (fr) | 2023-04-28 |
| PT3897595T (pt) | 2023-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191131T1 (hr) | Pripravak za zdravlje očiju | |
| Nowak | AMD ń THE RETINAL DISEASE WITH AN UNPRECISED ETIOPATHOGENE-SIS: IN SEARCH OF EFFECTIVE THERAPEUTICS | |
| JP2018534335A5 (hr) | ||
| Downie et al. | Oral omega-3 supplementation lowers intraocular pressure in normotensive adults | |
| CA2845868C (en) | Use of epa and dha in treating occular disorder | |
| Khatol et al. | Peroxisome proliferated activated receptors (PPARs): opportunities and challenges for ocular therapy | |
| HRP20230283T1 (hr) | Nutriceutički oftalmološki pripravak za liječenje patoloških stanja retine koja imaju neovaskularnu komponentu | |
| Semeraro et al. | Treatment of exudative age‐related macular degeneration with aflibercept combined with pranoprofen eye drops or nutraceutical support with omega‐3: A randomized trial | |
| Kim et al. | The leaves of Diospyros kaki exert beneficial effects on a benzalkonium chloride–induced murine dry eye model | |
| Shimura et al. | Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion | |
| HRP20192256T1 (hr) | Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta | |
| Daftarian et al. | Effects of intravitreal connective tissue growth factor neutralizing antibody on choroidal neovascular membrane-associated subretinal fibrosis | |
| Butler et al. | Very minimal fluence photodynamic therapy for chronic central serous chorioretinopathy | |
| RU2021117515A (ru) | Нутрицевтическая офтальмологическая композиция для лечения патологий сетчатки с неоваскулярным компонентом | |
| RU2407528C1 (ru) | Офтальмологическое противовоспалительное средство | |
| Norooznezhad et al. | How could cannabinoids be effective in multiple evanescent white dot syndrome? A hypothesis | |
| Novais et al. | Regression of drusen after combined treatment using photodynamic therapy with verteporfin and ranibizumab | |
| CN107898793B (zh) | 一种抑制近视的方法及制备药物的应用 | |
| Al Rashaed et al. | Acute bacterial endophthalmitis after intravitreal bevacizumab injection: Case report and literature review | |
| Cheng et al. | Rapid response to intravitreal aflibercept in neovascular age-related macular degeneration after development of tachyphylaxis to bevacizumab and ranibizumab | |
| Kawahara | Management of Dry Eye Disease in Asia: A Review | |
| Das | Pathological retinal angiogenesis and polyunsaturated fatty acids | |
| Lee et al. | Long-term results of intravitreal bevacizumab injection for macular edema: retinal vein obstruction and diabetic retinopathy | |
| Michels et al. | Branch Retinal Vein Occlusion–Update on Treatment Options | |
| Özmen | NEW DRUG STUDIES AND TREATMENT METHODS IN DIABETIC RETINOPATHY |